Antithrombin reduces ischemia/reperfusion-induced liver injury in rats by activation of cyclooxygenase-I

Thrombosis and Haemostasis

Volumn 92, Issue 3, 2004, Pages 550-558

  Harada, Naoaki ^a   Okajima, Kenji ^a   Uchiba, Mitsuhiro ^a   Kushimoto, Shigeki ^a   Isobe, Hirotaka ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Antithrombin; Cyclooxygenase; Ischemia reperfusion; Liver; PGE2; Prostacyclin

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; HEPARIN; ILOPROST; INDOMETACIN; ISOENZYME; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBIN INHIBITOR; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME ACTIVATION; INFLAMMATION; INHIBITION KINETICS; LIVER BLOOD FLOW; LIVER INJURY; LIVER ISCHEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; RAT; REPERFUSION;

6-KETOPROSTAGLANDIN F1 ALPHA; ANIMALS; ANTITHROMBIN III; CYCLOOXYGENASE 1; ENZYME ACTIVATION; ISOENZYMES; KINETICS; LIVER; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PROSTAGLANDINS E; RATS; RATS, WISTAR; REPERFUSION INJURY; RNA, MESSENGER;

EID: 4544331729     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH03-07-0460     Document Type: Article

References (50)

1. Rosenberg RD. Biochemistry of heparin antithrombin interactions, and the physiological role of this natural anticoagulant mechanism. Am J Med 1989; 87 Suppl. 3B: 2S-9S.
2. Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990; 59: 895-904.
3. Yamauchi T, Umeda F, Inoguchi T, et al. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Bichem Biophys Res Commun 1989; 163: 1404-11.
4. Eisenhut T, Sinha B, Grottrup-Wolfers E, et al. Prostacyclin analogs suppress the synthesis of tumor necrosis factor-a in LPS-stimulated human peripheral blood mononuclear cells. Immunopharmacology 1993; 26: 259-64.
5. Kainoh M, Imai R, Umetsu T, et al. Prostacyclin and beraprost sodium as suppressors of activated rat polymorphonuclear leukocytes. Biochem Pharmacol 1990; 39: 477-84.
6. Boxer LA, Allen JM, Schmidt M, et al. Inhibition of polymorphonuclear leukocyte adherence by prostacyclin. J Lab Clin Med 1980; 95: 672-8.
7. Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. Am J Physiol Gastointest Liver Physiol 2003; 284: G15-G26.
8. Harada N, Okajima K, Kushimoto S, et al. Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 1999; 93: 157-64.
9. Kuiper J, Zijlstra F, Kamps JAAM, et al. Identification of prostaglandin D2 as the major eicosanoid from liver endothelial and Kupffer cells. Biochim Biophys Acta 1988; 959: 143-52.
10. 2 protects against liver injury after Escherichia coli infection but hampers the resolution of the infection in mice. J Immunol 1998; 161: 3019-25.
11. Smith WL, Marnett LJ, DeWitt DL. Prostaglandin and thromboxane biosythesis. Pharmacol Ther 1991; 49: 153-79.
12. Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994; 90: 11693-7.
13. Mizutani A, Okajima K, Uchiba M, et al. Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 2003; 101: 3029-36.
14. Miller-Anderson M, Borg H, Anderson LO. Purification of antithrombin III by affinity chromatography. Thromb Res 1974; 5: 439-52.
15. Hayashi H, Chaudry IH, Clemens MG, et al. Hepatic ischemia models for determining the effects of ATP-MgCl2 treatment. J Surg Res 1986; 40: 167-75.
16. Lee SM, Clemens MG. Effect of α-tocopherol on hepatic mixed function oxidases in hepatic ischemia/reperfusion. Hepatology 1992; 15: 176-81.
17. Kushimoto S, Okajima K, Uchiba M, et al. Role of granulocyte elastase in ischemia/reperfusion injury of rat liver. Crit Care Med 1996; 24: 1908-12.
18. Okano J, Shiota G, Kawasaki H. Protective action of hepatocyte growth factor for acute liver injury caused by D-galactosamine in transgenic mice. Hepatology 1997; 26: 1241-9.
19. Shito M, Wakabayashi G, Ueda M, et al. Interleukin 1 receptor blockade reduces tumor necrosis factor production, tissue injury, and mortality after hepatic ischemia-reperfusion in the rat. Transplantation 1997; 63: 143-8.
20. Clark BD, Bedrosian I, Schindler R, et al. Detection of interleukin 1a and b in rabbit tissues during endotoxemia using sensitive radioimmunoassays. J Appl Physiol 1991; 71: 2412-8.
21. Warren JS, Yabroff KR, Remick DG, et al. Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat. J Clin Invest 1989; 84: 1873-82.
22. Tomomasa T, Ogawa T, Hikima A, et al. Developmental changes in cyclooxygenase mRNA expression in the gastric mucosa of rats. J Pediatr Gastroenterol Nutr 2002; 34: 169-73.
23. Karp GI, Marcum JA, Rosenberg RD. The role of tryptophan residues in heparin-antithrombin interactions. Arch Biochem Biophys 1984; 233: 712-20.
24. Okajima K, Ueyama H, Hashimoto Y, et al. Homozygous variant of antithrombin III that lacks affinity for heparin: AT III Kumamoto. Thromb Haemost 1989; 61: 20-24.
25. Okajima K, Abe H, Maeda S, et al. Antithrombin III Nagasaki (Ser116-Pro): a heterozygous variant with defective heparin binding associated with thrombosis. Blood 1993; 81: 1300-5.
26. Bajaj SP, Rapaport SI, Prodanos CA. A simplified procedure for purification of human prothrombin, factor IX and factor X. Prep Biochem 1981; 11: 397-412.
27. Morita T, Jackson CM: Localization of the structural difference between bovine blood coagulation factor XI and XII to tyrosine 18 in the activation peptide. J Biol Chem 1986; 261: 4008-14.
28. NeSheim ME, Kettner C, Shaw E, et al. Cofactor dependence of factor Xa incorporation into the prothrombinase complex. J Biol Chem 1981; 256: 6537-40.
29. Uchiba M, Okajima K, Abe H, et al. Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex. Thromb Res 1994; 74: 155-61.
30. 1a in rats. Thromb Res 1995; 80: 201-8.
31. Uchiba M, Okajima K, Murakami K, et al. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 1996; 270: L921-L930.
32. Arai I, Hamasaki Y, Futaki N, et al. Effect of NS-398, a new nonsteroidal anti-inflammatory agent, on gastric ulceration and acid secretion in rats. Res Commun Chem Pathol Pharmacol 1993; 81: 259-70.
33. 2 on gastric secretion, gastric release, and mucosal blood flow in dogs. Dig Dis Sci 1980; 25: 673-9.
34. Harada N, Okajima K, Kushimoto S. Gabexate mesilate, a synthetic protease inhibitor, reduces ischemia/reperfusion injury of rat liver by inhibiting leukocyte activation. Crit Care Med 1999; 27: 1958-64.
35. Armstrong JM, Chapple D, Dusting GJ, et al. Cardiovascular actions of prostacyclin (PGI2) in chloralose anesthetized dogs. Br J Pharmacol 1977; 61: 136-41.
36. Futaki N, Yoshikawa K, Hamasaka Y, et al. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 1993; 24: 105-10.
37. Futaki N, Arai I, Hamasaka Y, et al. Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. J Pharm Pharmacol 1993; 45: 753-5.
38. Sato H, Hashimoto M, Sugio K, et al. Comparative study between steroidal and non-steroidal antiinflammatory drugs on the mode of their actions on vascular permeability in rat carrageenan-air-pouch inflammation. J Pharmcobiodyn 1980; 3: 345-52.
39. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997; 24 Suppl. 49: 15-19.
40. Sunose Y, Takeyoshi I, Ohwada S, et al. The effect of cyclooxygenase-2 inhibitor FK3311 on ischemia-reperfusion injury in a canine total hepatic vascular exclusion model. J Am Coll Surg 2001; 192: 54-62.
41. Okajima K, Harada N, Kushimoto S, et al. Role of microthrombus formation in the development of ischemia/reperfusion-induced liver injury in rats. Thromb Haemost 2002; 88: 473-80.
42. Kawada N, Mizoguchi Y, Kobayashi K, et al. Possible induction of fatty acid cyclo-oxygenase in lipopolysaccharide-stimulated rat Kupffer cells. Gastroenterology 1992; 103: 1026-33.
43. Claveau D, Sirinyan M, Guay J, et al. Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E (2) production in the rat adjuvant-induced arthritis model. J Immunol 2003; 170: 4738-44.
44. Lazarus M, Kubata BK, Eguchi N, et al. Biochemical characterization of mouse microsomal prostaglandin E synthase-1 and its colocalization with cyclooxygenase-2 in peritoneal macrophages. Arch Biochem Biophys. 2002; 397: 336-41.
45. Kubes P, Payne D, Woodman RC. Molecular mechanisms of leukocyte recruitment in post-ischemic liver microcirculation. Am J Physiol Gastrointest Liver Physiol 2002; 283: G139-G147.
46. Okajima K, Harada N, Uchiba M. Microthrombus formation enhances tumor necrosis factor-α production in the development of ischemia/reperfusion-induced liver injury in rats. J Thromb Haemost 2003; 1: 1316-7.
47. Emerson TE, Fournel MA, Redens TB, et al. Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia. Am J Med 1989; 87 Suppl. 3B: 27S-33S.
48. Souter PJ, Thomas S, Hubbard AR, et al. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med 2001; 29: 134-9.
49. Dunzendorfer S, Kaneider N, Rabensteiner A, et al. Cell-surface heparin sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood 2001; 97: 1079-85.
50. Hoffmann JN, Vollmar B, Inthorn D, et al. Antithrombin reduces leukocyte adhesion during chronic endotoxemia by modulation of the cyclooxygenase pathway. Am J Physiol Cell Physiol 2000; 279: C98-C107.